Novo Nordisk A/S (NYSE:NVO) shares gapped up before the market opened on Tuesday . The stock had previously closed at $54.70, but opened at $55.30. Novo Nordisk A/S shares last traded at $56.32, with a volume of 657,608 shares.

Several research analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, May 2nd. Goldman Sachs Group Inc. lowered shares of Novo Nordisk A/S from a “conviction-buy” rating to a “buy” rating in a report on Tuesday, June 28th. Finally, Citigroup Inc. restated a “buy” rating on shares of Novo Nordisk A/S in a report on Friday, April 1st. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $61.00.

The firm has a market cap of $143.22 billion and a PE ratio of 28.27. The company’s 50-day moving average is $54.12 and its 200-day moving average is $54.23.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Friday, April 29th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.53 by $0.04. Equities research analysts expect that Novo Nordisk A/S will post $2.26 EPS for the current fiscal year.

A number of hedge funds and institutional investors have recently bought and sold shares of the company. Rhumbline Advisers increased its position in Novo Nordisk A/S by 5.6% in the fourth quarter. Rhumbline Advisers now owns 20,800 shares of the company’s stock worth $1,208,000 after buying an additional 1,100 shares during the period. Bronfman E.L. Rothschild L.P. purchased a new position in Novo Nordisk A/S during the fourth quarter worth $1,718,000. Deere & Co. increased its position in Novo Nordisk A/S by 1.3% in the fourth quarter. Deere & Co. now owns 31,581 shares of the company’s stock worth $1,834,000 after buying an additional 404 shares during the period. Financial Counselors Inc. increased its position in Novo Nordisk A/S by 5.7% in the fourth quarter. Financial Counselors Inc. now owns 36,727 shares of the company’s stock worth $2,133,000 after buying an additional 1,980 shares during the period. Finally, Pittenger & Anderson Inc. increased its position in Novo Nordisk A/S by 1.1% in the fourth quarter. Pittenger & Anderson Inc. now owns 49,119 shares of the company’s stock worth $2,853,000 after buying an additional 514 shares during the period.

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.